Cordis Global Medical Technology Fund is an Australian unit trust of actively-managed global listed companies which design and manufacture medical devices to treat critical chronic diseases.

This strategy aims to deliver attractive long-term returns by investing in a diversified portfolio of listed companies in developed and emerging markets, with significantly lower risk than the market. (For Wholesale Investors Only)

The Fund employs Contrarius’ valuation-based, contrarian investment philosophy and aims to achieve long-term returns higher than the benchmark, without greater risk of loss.

The aim of the fund is to achieve sustainable returns from capital growth, targetting 20% p.a.

The Fund is highly focussed on investing in long-term winners in attractive transforming markets when they are undervalued and offer outsized return potential.

The Manager aims to generate absolute returns of 8-12 per cent per annum over a 5-7 year investment cycle.

The Fund’s objective is to outperform the MSCI All Country World ex-Australia Net Total Return Index in Australian dollars over rolling 5 year periods.

The Fund seeks efficient index exposure with an active edge.

Designed to seek efficient index exposure with an active edge.

The principal objective of the Fund is to grow investor wealth over the long-term while maintaining a capital preservation focus by investing in a portfolio of Australian and International securities (For Wholesale Investors Only)

The Fund aims to outperform the MSCI All Country World Index over the investment cycle (typically 3-5 years).

The Fund aims to provide long-term capital growth and outperform the MSCI World ex Australia Net Total Return Index with lower risk over rolling three-year periods. (For Wholesale Investors Only)

A concentrated portfolio of outstanding global companies with clear strategies for creating long term value. (For Wholesale Investors only).

The Fund aims to achieve absolute returns in excess of the benchmark over the investment cycle (typically 3-5 years).

The Fund’s objective is to provide an attractive risk-adjusted return in excess of the Benchmark over a rolling 5–7-year period.